Carisma Therapeutics, a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focuses on developing immunotherapies for solid tumors, including CAR-M therapies CT-0508 and CT-0525. The company went public in February 2014 and employs 107 people.
CARM filed a patent for "anti-her2 chimeric antigen receptors and modified monocytes" on Fri, May 3, 2024.
📡️ Health Care
Patents
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.